ELT-2017 Inhibits Tumour Growth and Prevents Triple Negative Breast Cancer Invasion in Model Systems through Dysregulation of Ran-GTP

تفصيل البيانات البيبلوغرافية
الناشر:	السلط
المؤلف الرئيسي:	Al-Ramamneh, Rahmeh Saad (مؤلف)
مؤلفين آخرين:	Kandil, Yasser Ibrahim (Advisor), El-Tanani, Mohamed (Advisor)
التاريخ الميلادي:	2021
الصفحات:	1 - 71
رقم MD:	1210690
نوع المحتوى:	رسائل جامعية
اللغة:	English
قواعد المعلومات:	Dissertations
الدرجة العلمية:	رسالة ماجستير
الجامعة:	جامعة عمان الأهلية
الكلية:	عمادة الدراسات العليا والبحث العلمي
مواضيع:	العقاقير الطبية \| الخلايا السرطانية \| الاختبارات البيولوجية
رابط المحتوى:	صفحة العنوان المستخلص قائمة المحتويات 24 صفحة الأولى 1 الفصل 2 الفصل 3 الفصل 4 الفصل 5 الفصل الخاتمة المصادر والمراجع

صورة الغلاف

QR قانون

الوصف
المستخلص:	Triple negative breast cancer is one of the most aggressive tumors with dismal survival and a high death rate due to lake of any target therapy. Overexpression of the RAN GTP (RAN) gene has been shown to be linked to metastatic activity of MDA-MB-231 human breast cancer cells. The aim of this study was to investigate the potential of MELT-2017 as anticancer, targeted against the RAN gene, and to assess their effects in a range of biological assays. Methods The anticancer activity of MELT-2017 examined on MDA-MB-231 breast cancer cell line and A549 lung cancer cell line, using the [3-(4,5-dimetiltiazol-2-il)-2,5-difenil tetrazolium bromide] MTT assay. Inhibition of the cell cycle and increased apoptosis were analysed by flowcytometry [propidium iodide (PI) and Annexin V staining], Also the anti-metastatic activity of MELT-2017 was investigated by using migration, invasion and colony formation assays. Finally, the expression levels of RAN GTP (RAN) gene were assessed using quantitative RT-PCR. Results MELT-2017 inhibited cell proliferation in MDA-MB-231 breast cancer cell line and A549 lung cancer cell line (IC50 10.6 μM for MDA-MB-231 and 25.3 μM for A549 cells), Annexin V assay verified that the cytotoxic effect of MELT-2017 was through apoptotic pathway on both cell lines. Furthermore, MELT-2017 also suppressed invasion and migration, and down regulated RAN GTPase in both cell line. Conclusion Current findings suggest that MELT-2017 may be potential therapeutic agents against TNBC.